Skip to main content

Advertisement

SpringerLink
Log in

Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis

  • Research Article
  • Published:
Tumor Biology

Abstract

Deregulation of the endothelin system, comprised of endothelin-1 (ET-1), its isoforms (ET-2 and ET-3) and their receptors (ETAR and ETBR), is under investigation in various types of human cancer. ET-1 has been suggested to participate in breast cancer development and progression, while Big ET-1, its biological precursor, has also been found elevated in breast cancer patients. In the present study, we investigated plasma ET-1 and Big ET-1 levels in patients with suspicious mammographic lesions, in order to assess their potential application as diagnostic biomarkers in the early estimation of breast disease. The study consisted of 94 patients (Group A to 30 patients with invasive ductal carcinoma: Group B, 30 with ductal carcinoma in situ; and group C, 34 with papilloma or ductal hyperplasia), who underwent an image-guided vacuum-assisted breast biopsy, and 30 healthy controls (group D). ET-1 and Big ET-1 plasma levels were measured with enzyme-linked immunosorbent assay. ET-1 levels did not exhibit significant differences between patients and healthy controls (Group A to 0.92 fmol/mL; Group B: 0.90 fmol/mL; Group C: 0.66 fmol/mL; and Group D: 0.86 fmol/mL). In contrast, Big ET-1 levels were significantly higher in patients with invasive or in situ carcinoma compared to healthy controls (Group A: 0.69 fmol/mL; Group B, 0.62 fmol/mL; and group D: 0.39 fmol/mL; p < 0.001 and p < 0.01). Plasma Big ET-1 may provide a useful tool for the early detection of invasive or noninvasive ductal breast cancer. The utilization of such a diagnostic tool would greatly assist in the modern management of breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–5.

    CAS  PubMed  Google Scholar 

  2. Levin ER. Endothelins. N Engl J Med. 1995;333:356–63.

    CAS  PubMed  Google Scholar 

  3. Williams Jr DL, Jones KL, Colton CD, Nutt RF. Identification of high affinity endothelin-1 receptor subtypes in human tissues. Biochem Biophys Res Commun. 1991;180:475–80.

    CAS  PubMed  Google Scholar 

  4. Hoyer D, Waeber C, Palacios JM. [125I]endothelin-1 binding sites: autoradiographic studies in the brain and periphery of various species including humans. J Cardiovasc Pharmacol. 1989;13 Suppl 5:S162–5.

    CAS  PubMed  Google Scholar 

  5. Masaki T. Tissue specificity of the endothelin-induced responses. J Cardiovasc Pharmacol. 1991;17 Suppl 7:S1–4.

    CAS  PubMed  Google Scholar 

  6. Patel KV, Schrey MP. Human breast cancer cells contain a phosphoramidon-sensitive metalloproteinase which can process exogenous big endothelin-1 to endothelin-1: a proposed mitogen for human breast fibroblasts. Br J Cancer. 1995;71:442–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocrin Relat Cancer. 2007;14:233–44.

    CAS  Google Scholar 

  8. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86:485–98.

    CAS  PubMed  Google Scholar 

  9. Nelson JB, Chan-Tack K, Hedican SP, Magnuson SR, Opgenorth TJ, Bova GS, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–8.

    CAS  PubMed  Google Scholar 

  10. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 1999;59:720–7.

    CAS  PubMed  Google Scholar 

  11. Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol. 2000;157:1537–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Asham E, Shankar A, Loizidou M, Fredericks S, Miller K, Boulos PB, et al. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism. Br J Cancer. 2001;85:1759–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer. 2003;3:110–6.

    CAS  PubMed  Google Scholar 

  14. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab. 2003;14:44–50.

    CAS  PubMed  Google Scholar 

  15. Bagnato A, Spinella F, Rosanò L. Emerging role of the endothelin axis in ovarian tumor progression. Endocr Relat Cancer. 2005;12:761–72.

    CAS  PubMed  Google Scholar 

  16. Bagnato A, Tecce R, Di Castro V, Catt KJ. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res. 1997;57:306–11.

    Google Scholar 

  17. Pedram A, Razandi M, Hu RM, Levin ER. Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem. 1997;272:17097–103.

    CAS  PubMed  Google Scholar 

  18. Salani D, Taraboletti G, Rosanò L, Di Castro V, Borsotti P, Giavazzi R, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol. 2000;157:1703–11.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol. 2008;86:473–84.

    CAS  PubMed  Google Scholar 

  20. Alanen K, Deng DX, Chakrabarti S. Augmented expression of endothelin-1, endothelin-3 and the endothelin-B receptor in breast carcinoma. Histopathology. 2000;36:161–7.

    CAS  PubMed  Google Scholar 

  21. Kojima K, Nihei Z. Expression of endothelin-1 immunoreactivity in breast cancer. Surg Oncol. 1995;4:309–15.

    CAS  PubMed  Google Scholar 

  22. Yamashita J, Ogawa M, Inada K, Yamashita S, Matsuo S, Takano S. A large amount of endothelin-1 is present in human breast cancer tissues. Res Commun Chem Pathol Pharmacol. 1991;74:363–9.

    CAS  PubMed  Google Scholar 

  23. Yamashita J, Ogawa M, Sakai K. Prognostic significance of three novel biologic factors in a clinical trial of adjuvant therapy for node-negative breast cancer. Surgery. 1995;117:601–8.

    CAS  PubMed  Google Scholar 

  24. Wulfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Rody A, et al. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res. 2003;9:4125–31.

    PubMed  Google Scholar 

  25. Hagemann T, Binder C, Binder L, Pukrop T, Trümper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol. 2005;24:766–76.

    CAS  PubMed  Google Scholar 

  26. Yildirim Y, Gunel N, Coskun U, Sancak B, Bukan N, Aslan S, et al. Serum big endothelin-1 levels in female patients with breast cancer. Int Immunopharmacol. 2008;8:1119–23.

    CAS  PubMed  Google Scholar 

  27. Smollich M, Götte M, Fischgräbe J, Macedo LF, Brodie A, Chen S, et al. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole. Breast Cancer Res Treat. 2010;123:345–57.

    CAS  PubMed  Google Scholar 

  28. Fischgrabe J, Götte M, Michels K, Kiesel L, Wülfing P. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells. Int J Cancer. 2010;127:696–706.

    PubMed  Google Scholar 

  29. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, et al. Atrasentan Phase III Study Group Institutions. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007;110:1959–66.

    CAS  PubMed  Google Scholar 

  30. Chiappori AA, Haura E, Rodriguez FA, Boulware D, Kapoor R, Neuger AM, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res. 2008;14:1464–9.

    CAS  PubMed  Google Scholar 

  31. Kefford R, Beith JM, Van Hazel GA, Millward M, Trotter JM, Wyld DK, et al. A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs. 2007;25:247–52.

    CAS  PubMed  Google Scholar 

  32. Binder C, Hagemann T, Sperling S, Schulz M, Pukrop T, Grimshaw MJ, et al. Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis. Mol Cancer Ther. 2009;8:2452–60.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Wulfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Greb RR, et al. Endothelin-1, endothelin-A- and endothelin-B-receptor expression in preinvasive and invasive breast disease. Oncol Rep. 2004;11:791–6.

    PubMed  Google Scholar 

  34. Wülfing P, Tio J, Kersting C, Sonntag B, Buerger H, Wülfing C, et al. Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer. 2004;91:434–40.

    PubMed  PubMed Central  Google Scholar 

  35. Gasparini G. Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol. 2001;37:97–114.

    CAS  PubMed  Google Scholar 

  36. Wulfing P, Kersting C, Buerger H, Mattsson B, Mesters R, Gustmann C, et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer. 2005;92:1720–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C, Poremba C, et al. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res. 2004;10:2393–400.

    PubMed  Google Scholar 

  38. Abdel-Gawad IA, Hassanein HM, Bahgat NA, Abdel Sattar MA, El-Sissy AH, Altaweel MA, et al. Study of endothelin-1 and vascular endothelial growth factor in patients with cancer colon. J Egypt Natl Canc Inst. 2008;20:216–23.

    PubMed  Google Scholar 

  39. Moszynski R, Szpurek D, Michalak S, Szubert S, Sajdak S. The role of endothelin-1 and its correlation with CA125 levels, grayscale ultrasonography and doppler findings in differential diagnoses of ovarian tumors. Eur J Gynaecol Oncol. 2009;30:552–6.

    CAS  PubMed  Google Scholar 

  40. Strijbos MH, Gratama JW, Schmitz PI, Rao C, Onstenk W, Doyle GV, et al. Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer. 2010;46:2027–35.

    CAS  PubMed  Google Scholar 

  41. Ishibashi M, Fujita M, Nagai K, Kako M, Furue H, Haku E, et al. Production and secretion of endothelin by hepatocellular carcinoma. J Clin Endocrinol Metab. 1993;76:378–83.

    CAS  PubMed  Google Scholar 

  42. Hemsén A, Ahlborg G, Ottosson-Seeberger A, Lundberg JM. Metabolism of Big endothelin-1 (1-38) and (22-38) in the human circulation in relation to production of endothelin-1 (1-21). Regul Pept. 1995;55:287–97.

    PubMed  Google Scholar 

  43. Nelson JB, Opgenorth TJ, Fleisher LA, Frank SM. Perioperative plasma endothelin-1 and big endothelin-1 concentrations in elderly patients undergoing major surgical procedures. Anesth Analg. 1999;88:898–903.

    CAS  PubMed  Google Scholar 

  44. Simpson RA, Dickinson T, Porter KE, London NJ, Hemingway DM. Raised levels of plasma big endothelin 1 in patients with colorectal cancer. Br J Surg. 2000;87:1409–13.

    CAS  PubMed  Google Scholar 

  45. Smollich M, Götte M, Yip GW, Yong ES, Kersting C, Fischgräbe J, Radke I, Kiesel L, Wülfing P. On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Res Treat. 2007;106:361–9.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank AN Kastania for her contribution to this work. The study was financially supported by the Hellenic Anticancer Institute.

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Breast Unit, 1st Department of Propaedeutic Surgery, Hippokratio Hospital, University of Athens, Athens, Greece

    Vasileios Kalles, George C. Zografos, Paraskevi Liakou & Georgia Georgiou

  2. Research Center, Hellenic Anticancer Institute, 11 Valtetsiou St., Athens, 10680, Greece

    Xeni Provatopoulou, Eleni Kalogera, Alexandros Sagkriotis & Antonia Gounaris

  3. Department of Pathology, University of Athens, Athens, Greece

    Aphroditi Nonni

Authors
  1. Vasileios Kalles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George C. Zografos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xeni Provatopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eleni Kalogera
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Paraskevi Liakou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Georgia Georgiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alexandros Sagkriotis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Aphroditi Nonni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonia Gounaris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonia Gounaris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kalles, V., Zografos, G.C., Provatopoulou, X. et al. Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis. Tumor Biol. 33, 1231–1236 (2012). https://doi.org/10.1007/s13277-012-0371-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0371-x

Keywords

Search

Navigation